Lambiase, S.; Cavalloro, D.; Cioni, A.; Matteini, E.; Artosi, F.; Poscente, F.; Belardi, R.; Terrinoni, A.; Bernardini, S.; Bianchi, L.;
et al. A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes. J. Clin. Med. 2025, 14, 8170.
https://doi.org/10.3390/jcm14228170
AMA Style
Lambiase S, Cavalloro D, Cioni A, Matteini E, Artosi F, Poscente F, Belardi R, Terrinoni A, Bernardini S, Bianchi L,
et al. A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes. Journal of Clinical Medicine. 2025; 14(22):8170.
https://doi.org/10.3390/jcm14228170
Chicago/Turabian Style
Lambiase, Sara, Danilo Cavalloro, Arnaldo Cioni, Enrico Matteini, Fabio Artosi, Francesca Poscente, Riccardo Belardi, Alessandro Terrinoni, Sergio Bernardini, Luca Bianchi,
and et al. 2025. "A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes" Journal of Clinical Medicine 14, no. 22: 8170.
https://doi.org/10.3390/jcm14228170
APA Style
Lambiase, S., Cavalloro, D., Cioni, A., Matteini, E., Artosi, F., Poscente, F., Belardi, R., Terrinoni, A., Bernardini, S., Bianchi, L., Campione, E., & Diluvio, L.
(2025). A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes. Journal of Clinical Medicine, 14(22), 8170.
https://doi.org/10.3390/jcm14228170
